Table 6.
Regression results and WTP.
| Attributes of treatment | β | Coefficient (Standard error) | WTP (ten thousand) (95% CI) |
|---|---|---|---|
| Cost | β1 | −0.346*** (0.0173) | – |
| Progression-free survival 11 months (Reference level: 5 months) | β2 | 0.687*** (0.0748) | 1.986 (1.560; 2.412) |
| Progression-free survival 8 months (Reference level: 5 months) | β3 | 0.391*** (0.0590) | 1.129 (0.789; 1.470) |
| Disease control rate 90% (Reference level: 60%) | β4 | 0.690*** (0.0744) | 1.994 (1.583; 2.404) |
| Disease control rate 75% (Reference level: 60%) | β5 | 0.341*** (0.0668) | 0.985 (0.609; 1.362) |
| No rash (Reference level: Moderate rash) | β6 | 0.107 (0.0644) | 0.310 (−0.059; 0.680) |
| Mild rash (Reference level: Moderate rash) | β7 | 0.068 (0.0679) | 0.198 (−0.192; 0.588) |
| Mild nausea and vomiting (Reference level: Severe nausea and vomiting) | β8 | 0.372*** (0.0625) | 1.075 (0.693; 1.457) |
| Moderate nausea and vomiting (Reference level: Severe nausea and vomiting) | β9 | 0.139* (0.0604) | 0.402 (0.051; 0.754) |
| Mild Weakness and fatigue (Reference level: Severe Weakness and fatigue) | β10 | 0.457*** (0.0656) | 1.320 (0.918; 1.722) |
| Moderate Weakness and fatigue (Reference level: Severe Weakness and fatigue) | β11 | 0.175** (0.0627) | 0.507 (0.143; 0.872) |
| Infusion (Reference level: Oral) | β12 | 0.0381 (0.0476) | 0.110 (−0.159; 0.380) |
| Constant term | β13 | 0.0903 (0.0503) | – |
| Sample size | 202 | ||
| Observation value | 7,272 | ||
| log likelihood function | −2,050.0408 |
WTP presented in ten thousand RMB per month; 95% confidence intervals in parentheses.
*
Significant at 5% level,
**
significant at 10% level,
***
significant at 1% level.
Chi-square Test: χ2 = 52.78, P = 0.0000.